Filgrastim biosimilar - Mycenax BiotechAlternative Names: GranNEX
Latest Information Update: 04 Aug 2015
At a glance
- Originator Mycenax Biotech
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Neutropenia
Highest Development Phases
- Preregistration Neutropenia
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 04 Jun 2015 Filgrastim biosimilar - Mycenax Biotech is available for licensing in World as of 04 Jun 2015.